PDS Biotech reports 29.5-month median OS in low PD-L1 head and neck cancer cohort

PDS Biotechnology Corp

Median overall survival (mOS) of 29.5 months in CPS 1-19 cohort from VERSATILE-002 Phase 2 trial.
Published mOS for Keytruda monotherapy was 10.8 months; for Keytruda plus chemo 12.3 months.
Approximately 60% of trial patients (n=32) had low PD-L1 expression, a historically difficult-to-treat subset.
Data suggests PDS0101 + Keytruda may eliminate need for chemotherapy in this population.

item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.